ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
about
The role of neratinib in HER2-driven breast cancer.HER3 as a Therapeutic Target in Cancer.Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation.A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.Differential microRNA expression in the prefrontal cortex of mouse offspring induced by glyphosate exposure during pregnancy and lactation.The immunoglobulin-like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation.
P2860
Q38664492-B56AA9B3-9104-418E-BBB3-74FF9B69E34DQ38725101-14F908BF-E3F2-4F0C-BA35-0279248669A4Q39455125-28047639-38B9-4ACF-8DA6-95FC20513C0AQ46450905-D9458381-A04D-48E7-A653-215B55A0ABFBQ47158524-1BB3AAB7-6107-4C77-9D56-6EFF480C3AF3Q50186085-967EC120-238D-4495-AF1D-88CDE9748C41Q55516477-03337C14-9B49-4FF9-9A69-89F421CA834A
P2860
ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
ADAM10-mediated release of her ...... rastuzumab by activating HER3.
@en
type
label
ADAM10-mediated release of her ...... rastuzumab by activating HER3.
@en
prefLabel
ADAM10-mediated release of her ...... rastuzumab by activating HER3.
@en
P2093
P2860
P356
P1433
P1476
ADAM10-mediated release of her ...... rastuzumab by activating HER3.
@en
P2093
Eva A Ebbing
Hanneke W M van Laarhoven
Helene Damhofer
Jan Paul Medema
Kausilia K Krishnadath
Maarten F Bijlsma
Mark I van Berge Henegouwen
Sybren L Meijer
P2860
P304
10243-10254
P356
10.18632/ONCOTARGET.7200
P407
P577
2016-02-05T00:00:00Z